연구성과로 돌아가기

2023 연구자 정보 (32 / 1135)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Taylor, K.
(Taylor, K) ⓘ 		Amgen Ltd, Biostat, Uxbridge, Middx, England ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Tecson, K.
(Tecson, K) ⓘ 		Daiichi Sankyo Inc, Evidence Generat, Basking Ridge, NJ USA ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Tokunaga, Eriko
(Tokunaga, E) ⓘ 		Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04
[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 ⓘ 		SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Tsurutani, J.
(Tsurutani, J) ⓘ 		제1저자 Showa Univ Hosp, Adv Canc Translat Res Inst, Tokyo, Japan ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Tsurutani, Junji
(Tsurutani, J) ⓘ 		제1저자 Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04
[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 ⓘ 		SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Ueno, M.
(Ueno, M) ⓘ 		Kanagawa Canc Ctr, Gasteroenterol Dept, Yokohama, Kanagawa, Japan ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Valle, J. W.
(Valle, JW) ⓘ 		Christie NHS Fdn Trust, Med Oncol Dept, Manchester, Lancs, England ⓘ J-3571-2015
Valle, Juan ⓘ
ⓘ 		[JCR상위 1.1] Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Vogel, A.
(Vogel, A) ⓘ 		MHH Med Hsch Hannover, Gastro Hepato & Endocrinol Dept, Hannover, Germany ⓘ A-8437-2012
Vogel, Arndt ⓘ
ⓘ 		[JCR상위 1.1] Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Wang, X.
(Wang, X) ⓘ 		Zhejiang Canc Hosp, Med Oncol, Canc Res Inst, Hangzhou, Peoples R China
MIT, Cambridge, MA 02139 USA
MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC)
[JCR상위 6.7] Properties of Cosmic-Ray Sulfur and Determination of the Composition of Primary Cosmic-Ray Carbon, Neon, Magnesium, and Sulfur: Ten-Year Results from the Alpha Magnetic Spectrometer
[JCR상위 6.7] Temporal Structures in Electron Spectra and Charge Sign Effects in Galactic Cosmic Rays ⓘ 		SCIE ⓘ 1.1 ONCOLOGY
PHYSICS, MULTIDISCIPLINARY ⓘ 		ⓘ
Wang, Xiaojia
(Wang, XJ) ⓘ 		Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou, Peoples R China
Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04 ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Wennstig, A-K.
(Wennstig, AK) ⓘ 		Sundsvall Hosp, Oncol, Sundsvall, Sweden ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Wu, Xiaoqiang
(Wu, XQ) ⓘ 		Chengdu Univ, Sch Mech Engn, Chengdu 610106, Peoples R China ⓘ HSF-4010-2023
Wu, Xiaoqiang ⓘ
ⓘ 		[JCR상위 1.1] Exploration of metal organic frameworks and covalent organic frameworks for energy-related applications ⓘ SCIE ⓘ 1.1 CHEMISTRY, INORGANIC & NUCLEAR ⓘ Jiabao.yi@newcastle.edu.au;liang.qiao@uestc.edu.cn; ⓘ
Xu, Binghe
(Xu, BH) ⓘ 		CAMS, Canc Inst & Hosp, Beijing, Peoples R China ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04 ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Yamaguchi, K.
(Yamaguchi, K) ⓘ 		Canc Inst Hosp JFCR, Gastroenterol Chemotherapy Dept, Koto Ku, Tokyo, Japan ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Yamashita, T.
(Yamashita, T) ⓘ 		Kanagawa Canc Ctr, Breast Surg & Oncol, Yokohama, Kanagawa, Japan ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
페이지 이동: